EUVIMEDEUVIMED entdecken
Beobachtungsstudie

SQuID (subcutaneous insulin in diabetic ketoacidosis) II : Clinical and operational effectiveness

Richard T Griffey iD, Ryan M Schneider, Margo Girardi, Gina LaRossa, Julianne Yeary, Michael Lehmkuhl, Laura Frawley, Rachel Ancona, Taylor Kaser, Dan Suarez, Paulina Cruz-Bravo

Academic Emergency Medicine · 2025

DOI: 10.1111/acem.15020 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Academic Emergency Medicine, 2025. Verfasst von Richard T Griffey und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Diabetic Ketoacidosis, Hypoglycemic Agents, Insulin. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: AHRQ HHS, The Foundation for Barnes Jewish Hospital, Agency for Healthcare Research and Quality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We previously demonstrated safe treatment of low‐ to moderate‐severity (LTM) diabetic ketoacidosis (DKA) using the SQuID protocol (subcutaneous insulin in DKA) in a non–intensive care unit (ICU) observation setting, with decreased emergency department length of stay (EDLOS). Here, we expand eligibility to include sicker patients and admission to a regular medical floor and collected more detailed clinical data in a near‐real‐time fashion.

Methods

This is a real‐world, prospective, observational cohort study in an urban academic hospital (March 4, 2023–March 4, 2024). LTM DKA patients were treated with IV insulin (floor or ICU) or on SQuID. We compare fidelity (time to glargine and dextrose‐containing fluids), safety (rescue dextrose for hypoglycemia), effectiveness (time to anion gap closure, time on protocol), and operational efficiency (time to bed request, EDLOS, and ICU admission rate since implementation of the protocol).

Results

Of 84 patients with LTM DKA, 62 (74%) of were treated with SQuID and 22 (26%) with IV insulin. Fidelity was high in both groups. Rescue dextrose was required in five (8%) versus four (18%) patients, respectively (difference 9%, −31% to 10%). Compared to the IV insulin group, time to anion gap was 1.4 h shorter (95% CI −3.4 to 0.2 h) and time on protocol was 10.4 h shorter (95% CI −22.3 to −5.0 h) in SQuID patients. Median EDLOS was lower in the SQuID cohort 9.8 h (IQR 6.0–13.6) than the IV floor cohort 18.3 h (IQR 13.4–22.0 h), but longer than the overall IV insulin cohort. Since inception of SQuID, ICU admission rate in LTM DKA has decreased from 54% to under 21%.

Conclusions

In this single‐center study, we observed excellent fidelity, equivalent or superior safety, and clinical and operational effectiveness with SQuID compared to IV insulin. The SQuID protocol has become the de facto default pathway for treatment of LTM DKA. Since inception of SQuID, ICU admissions in LTM DKA have decreased 33%.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic KetoacidosisHypoglycemic AgentsInsulinAdultFemaleHumansMaleMiddle AgedEmergency Service, HospitalInjections, SubcutaneousLength of StayProspective StudiesTreatment OutcomeCohort Studies

Stichwörter der Autor:innen

diabetic ketoacidosisemergencysubcutaneous insulin

Substanzen

Hypoglycemic AgentsInsulin

Autor:innen und Institutionen

  • Department of Emergency Medicine, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
  • Department of Medicine, Division of Hospital Medicine, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
  • Barnes-Jewish Hospital Emergency Department, St. Louis, Missouri, USA.
  • Endocrinology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.

ORCID-Profile: Richard T Griffey

Förderung

  • AHRQ HHS
  • The Foundation for Barnes Jewish Hospital
  • Agency for Healthcare Research and Quality

Zitieren

APA

Griffey, R. T., Schneider, R. M., Girardi, M., LaRossa, G., Yeary, J., Lehmkuhl, M., Frawley, L., Ancona, R., Kaser, T., Suarez, D., & Cruz-Bravo, P. (2025). SQuID (subcutaneous insulin in diabetic ketoacidosis) II : Clinical and operational effectiveness. Academic Emergency Medicine. https://doi.org/10.1111/acem.15020

Vancouver

Griffey RT, Schneider RM, Girardi M, LaRossa G, Yeary J, Lehmkuhl M, et al. SQuID (subcutaneous insulin in diabetic ketoacidosis) II : Clinical and operational effectiveness. Academic Emergency Medicine. 2025. doi:10.1111/acem.15020

BibTeX
@article{Griffey2025,
  author = {Griffey, Richard T and Schneider, Ryan M and Girardi, Margo and LaRossa, Gina and Yeary, Julianne and Lehmkuhl, Michael and Frawley, Laura and Ancona, Rachel and Kaser, Taylor and Suarez, Dan and Cruz-Bravo, Paulina},
  title = {SQuID (subcutaneous insulin in diabetic ketoacidosis) II : Clinical and operational effectiveness},
  journal = {Academic Emergency Medicine},
  year = {2025},
  doi = {10.1111/acem.15020}
}
Kostenlos starten →